Scleraxis Inhibitors
Scleraxis (Scx) is a transcription factor crucial for the development and maintenance of tendons, ligaments, and other connective tissues. As a member of the basic helix-loop-helix (bHLH) family of transcription factors, Scx regulates the expression of genes involved in tendon development, extracellular matrix (ECM) synthesis, and tissue organization. During embryogenesis, Scx plays a pivotal role in tendon progenitor cell specification and differentiation, orchestrating the formation of functional tendon tissues essential for musculoskeletal function and locomotion. Furthermore, Scx expression persists in mature tendon tissues, where it continues to regulate ECM remodeling and homeostasis, contributing to tendon strength, elasticity, and overall tissue integrity.
Inhibition of Scx activity represents a strategy for modulating tendon development and function, as well as for investigating the molecular mechanisms underlying tendon-related pathologies. Several mechanisms can be employed to inhibit Scx function, including interference with its DNA-binding activity or disruption of its interactions with cofactors and transcriptional regulators. For instance, small molecule inhibitors or peptides targeting the DNA-binding domain of Scx could effectively disrupt its binding to target gene promoters, thereby attenuating the expression of genes essential for tendon development and maintenance. Additionally, modulation of upstream signaling pathways regulating Scx expression or activity, such as transforming growth factor-beta (TGF-β) or Wnt signaling, could provide alternative approaches for inhibiting Scx function. By elucidating the mechanisms of Scx inhibition, researchers can gain valuable insights into the molecular regulation of tendon development and homeostasis, as well as identify targets for tendon-related disorders.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
As a p38 MAPK inhibitor, SB203580 can indirectly modulate Scleraxis by impacting the p38 MAPK pathway, known for its role in stress responses and cell differentiation, processes where Scleraxis is active. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
A PI3K inhibitor, LY294002 can indirectly affect Scleraxis by influencing the PI3K/Akt pathway, crucial in various cellular processes including differentiation, potentially affecting Scleraxis-regulated pathways. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
An mTOR inhibitor, Rapamycin indirectly influences Scleraxis by affecting the mTOR pathway, which plays a significant role in cell growth and differentiation, processes in which Scleraxis is involved. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
A JNK inhibitor, SP600125 can modulate Scleraxis indirectly by impacting the JNK pathway, involved in cellular stress response and apoptosis, thereby potentially influencing Scleraxis activity. | ||||||
Y-27632, free base | 146986-50-7 | sc-3536 sc-3536A | 5 mg 50 mg | $186.00 $707.00 | 88 | |
A ROCK inhibitor, Y-27632 can indirectly affect Scleraxis activity by modulating cytoskeletal dynamics and cell morphology, which are important in mesenchymal cell differentiation where Scleraxis functions. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
A PI3K inhibitor, Wortmannin can indirectly modulate Scleraxis by impacting the PI3K/Akt pathway, thereby potentially influencing the differentiation pathways regulated by Scleraxis. | ||||||
Dasatinib | 302962-49-8 | sc-358114 sc-358114A | 25 mg 1 g | $70.00 $145.00 | 51 | |
A broad-spectrum tyrosine kinase inhibitor, Dasatinib can indirectly impact Scleraxis activity by inhibiting kinases involved in signaling pathways crucial for cell differentiation and proliferation. | ||||||
PF-562271 | 717907-75-0 | sc-478488 sc-478488A sc-478488B | 5 mg 10 mg 50 mg | $312.00 $474.00 $1124.00 | 3 | |
A FAK/Pyk2 inhibitor, PF-562271 can indirectly modulate Scleraxis by influencing focal adhesion kinase signaling, important in cell migration and differentiation. | ||||||
PP 2 | 172889-27-9 | sc-202769 sc-202769A | 1 mg 5 mg | $94.00 $227.00 | 30 | |
An Src family kinase inhibitor, PP2 can indirectly affect Scleraxis activity by modulating signaling pathways involved in cell adhesion and differentiation. | ||||||
DAPT | 208255-80-5 | sc-201315 sc-201315A sc-201315B sc-201315C | 5 mg 25 mg 100 mg 1 g | $40.00 $120.00 $480.00 $2141.00 | 47 | |
A γ-secretase inhibitor, DAPT can indirectly modulate Scleraxis by influencing Notch signaling, a pathway involved in cell differentiation processes where Scleraxis is active. | ||||||